Opexa Therapeutics, Inc., announced that its president and chief executive officer, Neil K. Warma, recently gave a presentation on immunotherapy and its potential for treating autoimmune disorders, including multiple sclerosis, at the recent Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact held at the Vatican. Neil…

Opexa Therapeutics announced that it has been named one of the “Top Projects to Watch” for the third consecutive year. A panel of independent experts recognized the biopharmaceutical company for its work in the development of personalized immunotherapies for autoimmune disorders, such as multiple sclerosis (MS) and neuromyelitis optica (NMO). Opexa was…

Cryoport, Inc., a leader in providing advanced cryogenic logistics solutions for the life sciences industry, has just announced it will be supplying Opexa Therapeutics’ lead personalized T-cell immunotherapy research initiatives for Multiple Sclerosis (MS) and Neuromyelitis Optica (“NMO”). Opexa’s breakthrough immunotherapy drug platform has shown the potential to improve the lives of…

Neuromyelitis optica (NMO), a rare autoimmune disorder often mistaken for multiple sclerosis, is similar in that it is characterized by myelin destruction in the optic nerves and spinal cord. In contrast to multiple sclerosis, as reported by the Transverse Myelitis Association, NMO does not initially affect…

After the Phase 2b clinical trial named Abili-T achieved full enrollment with 190 secondary progress multiple sclerosis (SPMS) patients, The Woodlands, Texas-based Opexa Therapeutics is patiently awaiting results for the company’s lead candidate, Tcelna, which are expected in the second half of 2016.

Opexa Therapeutics, Inc. a biopharmaceutical company headquartered in Woodlands, Texas, has announced the successful conclusion of negotiations amending its option and license agreement with Darmstadt, Germany based pharma multinational Merck’s “Merck Serono” division. Under terms of the revised agreement, Opexa will receive a $3 million payment to…

The National Multiple Sclerosis Society‘s Lone Star Chapter, which is sponsoring the nonprofit organization’s annual Houston-area Walk MS fundraisers, has announced that Woodlands-based biopharmaceutical company Opexa Therapeutics, a company currently developing personalized immunotherapies for multiple sclerosis (MS), will also support the fundraising effort. This is the fourth consecutive…

Opexa Therapeutics, Inc., a drug delivery company based in The Woodlands, Texas, has been making significant progress in researching and developing Tcelna®, a breakthrough T-cell immunotherapy for multiple sclerosis (MS). The company recently announced they have reached their enrollment mark for conducting a Phase IIb clinical trial to test Tcelna as a viable…